switching from semaglutide to tirzepatide reviews vs. for Weight Loss Experiences switching from semaglutide to

SYNERGY-NASH: Tirzepatide and metabolic steatohepatitis (MASH) SYNERGY-NASH (Loomba et al., NEJM 2024, NEJMoa2401943, PMID 38856224) is a phase 2 trial in 190 patients with metabolic steatohepatitis (MASH) and biopsy-proven stage 2 or 3 fibrosis

The FDA and Novo Nordisk did not immediately respond to requests for comment

The FDA-approved Prescribing Information for tirzepatide (Mounjaro and Zepbound) includes specific warnings and precautions regarding pancreatic safety, reflecting ongoing pharmacovigilance for this medication class

Important Note: Important Note: This information is for educational purposes only and should not be interpreted as medical advice

Compounded vials are typically kept refrigerated (2-8 C), protected from light because B12 is light-sensitive, and discarded per the compounder's beyond-use date

GLP-1 medications like Ozempic and Zepbound have been heralded for their unparalleled success in treating obesity and type 2 diabetes